Novartis reports tumour cases in children treated with SMA gene therapy
Novartis reports tumour cases in children treated with SMA gene therapy
Novartis reports tumour cases in children treated with SMA gene therapy
Key points
اہم نکات
मुख्य बातें
- Novartis has acknowledged seven previously unknown cases of tumours in children treated with its spinal muscular atrophy gene therapy Zolgensma, STAT reports.
- In total the company has received nine tumour reports since the treatment was approved in 2019, and in two cases there was evidence the therapy's viral vector had integrated into the patients' DNA.
- A causal link has not been established, and regulators are now examining the cases.
- Novartis has acknowledged seven previously unknown cases of tumours in children treated with its spinal muscular atrophy gene therapy Zolgensma, STAT reports.
- In total the company has received nine tumour reports since the treatment was approved in 2019, and in two cases there was evidence the therapy's viral vector had integrated into the patients' DNA.
- A causal link has not been established, and regulators are now examining the cases.
- Novartis has acknowledged seven previously unknown cases of tumours in children treated with its spinal muscular atrophy gene therapy Zolgensma, STAT reports.
- In total the company has received nine tumour reports since the treatment was approved in 2019, and in two cases there was evidence the therapy's viral vector had integrated into the patients' DNA.
- A causal link has not been established, and regulators are now examining the cases.
Novartis has acknowledged seven previously unknown cases of tumours in children treated with its spinal muscular atrophy gene therapy Zolgensma, STAT reports. In total the company has received nine tumour reports since the treatment was approved in 2019, and in two cases there was evidence the therapy's viral vector had integrated into the patients' DNA. A causal link has not been established, and regulators are now examining the cases. More than 6,000 patients have received Zolgensma, and the two patients whose tumours showed vector integration have been treated and remain under monitoring.
Novartis has acknowledged seven previously unknown cases of tumours in children treated with its spinal muscular atrophy gene therapy Zolgensma, STAT reports. In total the company has received nine tumour reports since the treatment was approved in 2019, and in two cases there was evidence the therapy's viral vector had integrated into the patients' DNA. A causal link has not been established, and regulators are now examining the cases. More than 6,000 patients have received Zolgensma, and the two patients whose tumours showed vector integration have been treated and remain under monitoring.
Novartis has acknowledged seven previously unknown cases of tumours in children treated with its spinal muscular atrophy gene therapy Zolgensma, STAT reports. In total the company has received nine tumour reports since the treatment was approved in 2019, and in two cases there was evidence the therapy's viral vector had integrated into the patients' DNA. A causal link has not been established, and regulators are now examining the cases. More than 6,000 patients have received Zolgensma, and the two patients whose tumours showed vector integration have been treated and remain under monitoring.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।